University of Southampton: against COVID-19 University
Entity: University of Southampton
Category: University
Description: The University of Southampton (abbreviated as Soton in post-nominal letters) is a research university in Southampton, England. The university's origins date back to the founding of the Hartley Institution in 1862. In 1902, the Institution developed into the Hartley University College, awarding degrees from the University of London. On 29 April 1952, the institution was granted full university status, allowing it to award its own degrees. Researchers at University Hospital Southampton (UHS) and the University of Southampton are set to begin trials of a vaccine pioneered in the UK which could protect against COVID-19.
Project: ACE-Inhibitors/Angiotensin Receptor Blockers and risk of death for people infected with COVID-19 - a prospective cohort study.
Research Group: Prevention Group, Primary Care Unit
Project Description: Analysis of RCGP Research Surveillance data of routinely collected GP records from May to August 2020 covering 530 practices. In the UK, as of 24th March 2020, there were 8077 cases and 422 deaths from COVID-19. This figure is predicted to rise. Globally, mortality rates and severe complications have been high amongst those with hypertension (23.7%), cardiovascular disease (8%) or type 2 diabetes (16.2%). (Guan et al., 2020; Wu et al., 2020; Yang et al., 2020) Reports from the COVID-19 epicentre in China and a recent letter in the Lancet noted that amongst those with severe complications including death, ACE-I and ARBs were frequently prescribed. (Fang, Karakiulakis and Roth, 2020) COVID-19 binds to target cells through angiotensin-converting enzyme 2 (ACE2) which is expressed by epithelial cells in the lungs, kidneys and blood vessels. ACE-I and ARBs are thought to increase the expression of ACE2. It is hypothesised that these medications, therefore, make people more susceptible to COVID-19 and could also increase the severity of the infection leading to ARDS and death.(Patel and Verma, 2020) (Jia et al., 2005) This has caused some concern amongst prescribers and is leading to non-compliance amongst patients such that the British and Irish Hypertension Society, European Hypertension Society, Renal Association have released position statements calling for urgent evidence. While a mechanistic link is plausible, to date, there are no studies in human subjects while animal models show mixed results. Given that 65 million prescriptions of ARB/ACE-I have been issued by GPs in the UK in the last year alone and the COVID-19 epidemic is close to reaching its peak, it is essential and timely that this hypothesis is tested.
Collaborators: Dr Hajira Dambha-Miller, Prof Paul Little, Dr Beth Stuart, Dr Simon Fraser (University of Southampton), Prof Julia Hippisley-Cox, Prof Simon de Lusignan, Dr Ali Alrasbi, Mr William Hinton (University of Oxford).
Category: University
Description: The University of Southampton (abbreviated as Soton in post-nominal letters) is a research university in Southampton, England. The university's origins date back to the founding of the Hartley Institution in 1862. In 1902, the Institution developed into the Hartley University College, awarding degrees from the University of London. On 29 April 1952, the institution was granted full university status, allowing it to award its own degrees. Researchers at University Hospital Southampton (UHS) and the University of Southampton are set to begin trials of a vaccine pioneered in the UK which could protect against COVID-19.
Project: ACE-Inhibitors/Angiotensin Receptor Blockers and risk of death for people infected with COVID-19 - a prospective cohort study.
Research Group: Prevention Group, Primary Care Unit
Project Description: Analysis of RCGP Research Surveillance data of routinely collected GP records from May to August 2020 covering 530 practices. In the UK, as of 24th March 2020, there were 8077 cases and 422 deaths from COVID-19. This figure is predicted to rise. Globally, mortality rates and severe complications have been high amongst those with hypertension (23.7%), cardiovascular disease (8%) or type 2 diabetes (16.2%). (Guan et al., 2020; Wu et al., 2020; Yang et al., 2020) Reports from the COVID-19 epicentre in China and a recent letter in the Lancet noted that amongst those with severe complications including death, ACE-I and ARBs were frequently prescribed. (Fang, Karakiulakis and Roth, 2020) COVID-19 binds to target cells through angiotensin-converting enzyme 2 (ACE2) which is expressed by epithelial cells in the lungs, kidneys and blood vessels. ACE-I and ARBs are thought to increase the expression of ACE2. It is hypothesised that these medications, therefore, make people more susceptible to COVID-19 and could also increase the severity of the infection leading to ARDS and death.(Patel and Verma, 2020) (Jia et al., 2005) This has caused some concern amongst prescribers and is leading to non-compliance amongst patients such that the British and Irish Hypertension Society, European Hypertension Society, Renal Association have released position statements calling for urgent evidence. While a mechanistic link is plausible, to date, there are no studies in human subjects while animal models show mixed results. Given that 65 million prescriptions of ARB/ACE-I have been issued by GPs in the UK in the last year alone and the COVID-19 epidemic is close to reaching its peak, it is essential and timely that this hypothesis is tested.
Collaborators: Dr Hajira Dambha-Miller, Prof Paul Little, Dr Beth Stuart, Dr Simon Fraser (University of Southampton), Prof Julia Hippisley-Cox, Prof Simon de Lusignan, Dr Ali Alrasbi, Mr William Hinton (University of Oxford).
Technology:
COVID Labs/Universities
Industry:
COVID R&D
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership